Concepts (91)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Conjunctival Neoplasms | 3 | 2024 | 4 | 2.570 |
Why?
|
| Sarcoma, Kaposi | 7 | 2023 | 52 | 2.510 |
Why?
|
| HIV Infections | 19 | 2024 | 4946 | 1.980 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2024 | 32 | 1.970 |
Why?
|
| Uterine Cervical Neoplasms | 7 | 2023 | 113 | 1.790 |
Why?
|
| Neoplasms | 7 | 2024 | 141 | 1.710 |
Why?
|
| Papillomavirus Infections | 5 | 2024 | 72 | 0.990 |
Why?
|
| Breast Neoplasms | 2 | 2023 | 128 | 0.960 |
Why?
|
| Head and Neck Neoplasms | 1 | 2023 | 4 | 0.910 |
Why?
|
| Bone Neoplasms | 1 | 2023 | 6 | 0.910 |
Why?
|
| Incidence | 9 | 2024 | 655 | 0.680 |
Why?
|
| Humans | 24 | 2024 | 14077 | 0.630 |
Why?
|
| South Africa | 15 | 2024 | 7312 | 0.580 |
Why?
|
| Female | 16 | 2024 | 8751 | 0.570 |
Why?
|
| Male | 13 | 2024 | 6489 | 0.440 |
Why?
|
| Herpesvirus 8, Human | 2 | 2023 | 14 | 0.420 |
Why?
|
| Adult | 10 | 2024 | 5664 | 0.390 |
Why?
|
| Seroepidemiologic Studies | 3 | 2024 | 104 | 0.330 |
Why?
|
| Registries | 3 | 2024 | 89 | 0.310 |
Why?
|
| Middle Aged | 7 | 2024 | 3425 | 0.300 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2024 | 2 | 0.240 |
Why?
|
| Ultraviolet Rays | 1 | 2023 | 7 | 0.230 |
Why?
|
| HIV Seropositivity | 2 | 2023 | 263 | 0.220 |
Why?
|
| Papillomavirus Vaccines | 1 | 2023 | 17 | 0.220 |
Why?
|
| Young Adult | 4 | 2021 | 2357 | 0.210 |
Why?
|
| Cohort Studies | 2 | 2022 | 939 | 0.200 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 29 | 0.200 |
Why?
|
| Adolescent | 4 | 2021 | 2858 | 0.200 |
Why?
|
| Antibodies, Viral | 1 | 2024 | 266 | 0.200 |
Why?
|
| Alcoholism | 1 | 2021 | 17 | 0.200 |
Why?
|
| Herpesvirus 4, Human | 1 | 2021 | 5 | 0.190 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2021 | 6 | 0.190 |
Why?
|
| Case-Control Studies | 4 | 2024 | 464 | 0.190 |
Why?
|
| Smoking | 1 | 2021 | 99 | 0.190 |
Why?
|
| Papillomaviridae | 1 | 2021 | 33 | 0.180 |
Why?
|
| Hematologic Neoplasms | 1 | 2020 | 4 | 0.180 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 186 | 0.180 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 47 | 0.180 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 1377 | 0.170 |
Why?
|
| Anti-Retroviral Agents | 2 | 2023 | 542 | 0.170 |
Why?
|
| Child | 2 | 2022 | 2180 | 0.160 |
Why?
|
| HIV | 3 | 2023 | 380 | 0.130 |
Why?
|
| Anti-HIV Agents | 1 | 2023 | 1275 | 0.120 |
Why?
|
| HIV-1 | 1 | 2023 | 1239 | 0.120 |
Why?
|
| Aged | 3 | 2024 | 1650 | 0.110 |
Why?
|
| Life Style | 2 | 2022 | 80 | 0.100 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2021 | 654 | 0.080 |
Why?
|
| Prevalence | 2 | 2022 | 1149 | 0.080 |
Why?
|
| Risk Factors | 2 | 2024 | 1431 | 0.080 |
Why?
|
| Pregnancy | 2 | 2022 | 1815 | 0.070 |
Why?
|
| Vulvar Neoplasms | 1 | 2024 | 1 | 0.060 |
Why?
|
| Penile Neoplasms | 1 | 2024 | 2 | 0.060 |
Why?
|
| Human papillomavirus 18 | 1 | 2024 | 7 | 0.060 |
Why?
|
| Human papillomavirus 16 | 1 | 2024 | 7 | 0.060 |
Why?
|
| Anus Neoplasms | 1 | 2024 | 4 | 0.060 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2024 | 4 | 0.060 |
Why?
|
| Vaginal Neoplasms | 1 | 2024 | 3 | 0.060 |
Why?
|
| Advisory Committees | 1 | 2024 | 12 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2024 | 7 | 0.060 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2023 | 1 | 0.060 |
Why?
|
| Hormones | 1 | 2023 | 9 | 0.060 |
Why?
|
| United States | 1 | 2023 | 129 | 0.050 |
Why?
|
| Health Priorities | 1 | 2024 | 62 | 0.050 |
Why?
|
| Lipoproteins, HDL | 1 | 2022 | 9 | 0.050 |
Why?
|
| Early Detection of Cancer | 1 | 2023 | 37 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2022 | 10 | 0.050 |
Why?
|
| Glucose | 1 | 2022 | 45 | 0.050 |
Why?
|
| Cholesterol | 1 | 2022 | 38 | 0.050 |
Why?
|
| Multimorbidity | 1 | 2022 | 42 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2022 | 43 | 0.050 |
Why?
|
| Poverty | 1 | 2023 | 149 | 0.050 |
Why?
|
| Contraceptive Agents | 1 | 2022 | 27 | 0.050 |
Why?
|
| Hospitals, Teaching | 1 | 2021 | 21 | 0.050 |
Why?
|
| Zimbabwe | 1 | 2022 | 115 | 0.050 |
Why?
|
| Parity | 1 | 2021 | 19 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2021 | 26 | 0.050 |
Why?
|
| Africa South of the Sahara | 1 | 2022 | 328 | 0.050 |
Why?
|
| Logistic Models | 1 | 2021 | 252 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2021 | 89 | 0.050 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2020 | 14 | 0.050 |
Why?
|
| Age Distribution | 1 | 2021 | 106 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2021 | 131 | 0.050 |
Why?
|
| Public Health Surveillance | 1 | 2020 | 52 | 0.040 |
Why?
|
| Mortality | 1 | 2021 | 101 | 0.040 |
Why?
|
| Data Collection | 1 | 2020 | 86 | 0.040 |
Why?
|
| Age Factors | 1 | 2020 | 364 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 449 | 0.040 |
Why?
|
| Africa | 1 | 2020 | 360 | 0.040 |
Why?
|
| Time Factors | 1 | 2020 | 503 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2020 | 1675 | 0.030 |
Why?
|
| Infant | 1 | 2020 | 2145 | 0.030 |
Why?
|